Nventa Biopharmaceuticals Corporation Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (1999)
Status: Acquired by Akela Pharma, Inc. (2009)

Organization Overview

First Clinical Trial
2001
NCT00038714
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

sgn-00101 (1 trial)

Drugs in Phase 1 Trials (2)

poly-iclc (1 trial)

Verpasep (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma in Situ (Phase 1)

Cervical Intraepithelial Neoplasia (Phase 1)

Neoplasms (Phase 1)

Papilloma (Phase 2)

Papillomavirus Infections (Phase 2)

Respiratory Tract Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3